PMID: 20647696Jul 22, 2010Paper

Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer

Gan to kagaku ryoho. Cancer & chemotherapy
Kenji Hashimoto, Kenji Tamura

Abstract

PARP and BRCA are both known as DNA repair enzymes. Functional loss of BRCA cell with PARP inhibition indicates apoptosis. Triple negative breast(TNB)cancer(estrogen receptor-negative, progesterone receptor-negative, HER-2 expression negative)are well associated with basal-type breast cancer. Basal-type breast cancer often has loss of BRCA and showed poor clinical outcomes. Considering the similar molecular profiles of Basal-type breast cancer and TNB cancer, clinical trials using PARP inhibitor for patients with TNB cancer has been warranted. A randomized phase II trial comparing gemcitabine and carboplatin(GC)to GC plus BSI-201(PARP inhibitor)in patients with metastatic TNB cancer showed significantly longer progression-free survival and overall survival. We herein summarized up-to-date knowledge of PARP inhibitor in association with TNB and BRCA.

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis